BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37428268)

  • 21. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I; Oprescu FA; Rullo E; Ascoli V
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New developments in mesothelial pathology.
    Churg A
    Histopathology; 2024 Jan; 84(1):136-152. PubMed ID: 37694811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
    Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
    Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S
    Pathology; 2024 May; ():. PubMed ID: 38789301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
    Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
    Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
    Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
    Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
    Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
    Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
    Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
    Chapel DB; Husain AN; Krausz T; McGregor SM
    Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BAP1 GERMLINE MUTATION WITH IRIDOCILIOCHOROIDAL MELANOMA AND MALIGNANT PERITONEAL MESOTHELIOMA.
    Yaghy A; Lim LA; Mashayekhi A; Shields CL
    Retin Cases Brief Rep; 2022 Mar; 16(2):194-198. PubMed ID: 31895725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
    Baumann F; Flores E; Napolitano A; Kanodia S; Taioli E; Pass H; Yang H; Carbone M
    Carcinogenesis; 2015 Jan; 36(1):76-81. PubMed ID: 25380601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
    Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC
    Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ.
    Dacic S; Roy S; Lyons MA; von der Thusen JH; Galateau-Salle F; Churg A
    Lung Cancer; 2020 Nov; 149():1-4. PubMed ID: 32932212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
    Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
    Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
    Kittaneh M; Berkelhammer C
    J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
    Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
    Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
    De Rienzo A; Chirieac LR; Hung YP; Severson DT; Freyaldenhoven S; Gustafson CE; Dao NT; Meyerovitz CV; Oster ME; Jensen RV; Yeap BY; Bueno R; Richards WG
    J Pathol; 2021 Jan; 253(1):68-79. PubMed ID: 32944962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.